Groupe d'Etude en Oncologie du Quebec

Title	A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
Protocole ID	GO45416
ClinicalTrials.gov ID	NCT06619587
Cancer Type(s)	Non Small Cells - Lung
Phase	Phase I-II
Stage	Advanced or metastatic disease
Study Type	Clinical
Drug	GDC-7035 seul et en association avec d'autres traitements antinéoplasiques
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
City
Principal Investigator	Dr. à venir
Coordinator	Benedicte Foveau 514-340-8222 poste 25981
Status	Recruiting
Activation Date
Eligibility Criteria	Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm
Exclusion Criteria	Malabsorption or other condition that would interfere with enteral absorption Active brain metastases Clinically significant cardiovascular dysfunction or liver disease

Groupe d'étude en oncologie du Québec